AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 23 May 2026
2026-01-19 10:30:00 Monday ET

Andy Yeh Alpha (AYA) fintech network platform: major milestones, key product features, and online social media services Introduction
2018-09-17 12:40:00 Monday ET

Nobel Laureate Robert Shiller's long-term stock market indicator points to a recent peak. His cyclically-adjusted P/E ratio (or CAPE) accounts for long-
2020-07-26 15:29:00 Sunday ET

Firms and customers create value and wealth together by joining the continual flow of small batches of lean production to the lean consumption of cost-effec
2019-01-03 10:38:00 Thursday ET

American parents often worry about money and upward mobility for their children. A recent New York Times survey suggests that nowadays American parents spen
2019-07-13 07:17:00 Saturday ET

Japanese prime minister Shinzo Abe outlines the main economic priorities for the G20 summit in Osaka, Japan. First, Asian countries need to forge the key Re
2020-05-21 11:30:00 Thursday ET

Most blue-ocean strategists shift fundamental focus from current competitors to alternative non-customers with new market space. W. Chan Kim and Renee Ma